Articles

Videos

Podcasts

Clinical Role

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Chemotherapy May Eliminate Need for Allogeneic Stem Cell Transplant for Newly Diagnosed Patients with ALL, Relapsed/Refractory ALL 

Relapses remain a challenge in treating patients with leukemia.

Dual CAR T-Cell Therapy for Leukemia Could Impact Safety, Different Population of Cells 

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

FDA Approves Diagnostic Test to Identify Patients with Metastatic Breast Cancer Expressing Low Levels of HER2 Protein

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

An Integrative Efficacy Score May Be Effective to Evaluate Drug Benefit in Oncology

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Mosunetuzumab Shows Efficacy in Patients With Follicular Lymphoma 

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

FDA Grants Accelerated Approval to Futibatinib for Locally Advanced, Metastatic Cholangiocarcinoma

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

Celebrating Pharmacists During American Pharmacists Month 2022

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

Pharmacy Times and Parata Systems Announce the 2022 Next-Generation Pharmacist Award Winners

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Understanding of Mutations Influences Treatment for Patients With Waldenstrom Macroglobulinemia

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

Belantamab Mafodotin Combination Shows Durable Efficacy in Relapsed or Refractory Multiple Myeloma 

® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.

Specialty Pharmacy